Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer.
OBJECTIVE
The aim of this study was to investigate the change of 3'-[¹⁸F]fluoro-3'-deoxy-L: -thymidine (¹⁸FLT) uptake in normal bone marrow (BM) after inevitable radiation.


METHODS
Twenty-one non-small cell lung cancer patients who received carbon ion radiotherapy (CIRT) were studied with ¹⁸FLT-positron emission tomography/computed tomography (PET/CT) at pre- and post-CIRT. Radiation dose was calculated by radiation planning. Irradiated BM was divided into three groups (<10% of maximum dose, 10-30%, and >30%).


RESULTS
¹⁸FLT uptake clearly decreased at >10% irradiated areas and mildly decreased at <10% areas. ¹⁸FLT uptake was lowest just after CIRT, somewhat increased at 3 months, and remained unchanged for more than 1 year. There was no significant difference between 10-30% and >30% areas.


CONCLUSIONS
¹⁸FLT revealed that BM function decreased by small dose such as <4.2-4.4 GyE/1 fraction of CIRT and is eradicated by >4.2-4.4 GyE/1 fraction.
Koizumi
Mitsuru
M
Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. mitsuru@nirs.go.jp.|Molecular Imaging Center, National Institute of Radiological Sciences, Anagawa 4-9-1, Inageku, Chiba, Japan. mitsuru@nirs.go.jp.
Saga
Tsuneo
T
Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Inubushi
Masayuki
M
Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Fukumura
Toshimitsu
T
Molecular Probe, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Yoshikawa
Kyosan
K
Molecular Imaging Center and Clinical Diagnosis Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Yamamoto
Naoyoshi
N
Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Nakajima
Mio
M
Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Sugane
Toshio
T
Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Baba
Masayuki
M
Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
D000368:Aged; D001853:Bone Marrow / Q000000981:diagnostic imaging* / Q000528:radiation effects*; D002244:Carbon / Q000627:therapeutic use*; D049109:Cell Proliferation; D003710:Demography; D015224:Dideoxynucleosides / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007477:Ions; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014057:Tomography, X-Ray Computed
D015224:Dideoxynucleosides; D007477:Ions; D019275:Radiopharmaceuticals; D002244:Carbon; C002854:alovudine